HealthDay News – For patients receiving an everolimus-eluting stent implantation, 6 months of dual antiplatelet therapy (DAPT) does not increase composite events compared with 12 months of DAPT, according to a study published online May 17 in JACC: Cardiovascular Interventions to coincide with EuroPCR 2016, held from May 17 to 20 in Paris.
Sung-Jin Hong, MD, from Inje University in Seoul, South Korea, and colleagues randomized 1400 patients (implanted mean total stent length >45 mm) receiving an everolimus-eluting stent implantation to receive 6-month (699 patients) or 12-month (701 patients) DAPT.
Researchers found that the primary end point (composite of cardiac death, myocardial infarction, stroke, or thrombolysis in myocardial infarction [TIMI] major bleeding at 1 year) occurred in 2.2% and 2.1% of patients in the 6- and 12-month DAPT groups, respectively (hazard ratio [HR]: 1.07; P=.854).
Definite or possible stent thrombosis occurred in 0.3% of patients in both the 6- and 12-month groups (HR: 1.00; P=.999). No significant differences were seen between the groups in the primary end point among 686 patients with acute coronary syndrome and 506 patients with diabetes.
“Compared to 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in the patients who received an everolimus-eluting stent implantation,” the authors wrote.
Disclosures: The study was partially funded by Abbott Vascular.
Hong S-J, Shin D-H, Kim J-S, et al. 6-month vs 12-month dual antiplatelet therapy following long everolimus-eluting stent implantation. The IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv. 2016. doi: 10.1016/j.jcin.2016.04.036.